Insiders Trades
Sera Prognostics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 16 Jun 2022.
Sera Prognostics, Inc.: what insiders have been doing
Sera Prognostics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 80 filings came from 22 insiders.
All open-market trades in the period are sales: 43 sales worth €396k, by 10 insiders, with no purchase on record. The totals do not cover 3 filings with an undisclosed amount. Biggest ticket of the year: €74k, sold by Lindgardt Zhenya and made public on 10 December 2025.
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 80 filings, this issuer sits above that mark. Looking back to 2021, when coverage begins, insiders filed 1 purchase and 169 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 81,000 USD and net income of -31.9 m USD.
Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
264
Thresholds
n/a
Buy Volume
€9,195
1 ops. · all time
Sell Volume
€4M
169 ops. · all time
Who traded when
BuySaleHarrison Robert Gardner22 sales
Aerts Austin17 sales
Lindgardt Zhenya14 sales
Kearney Paul13 sales
Mansoor Raza Mirza13 sales
Benjamin Jackson12 sales
+5 other insiders
Since the insiders bought
- +178.0%Entry US$1.27 · Close at T+365 US$3.53
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.07
Analyst consensus
2 analysts1.00/5
US$5.00Target US$5.50(+166%)US$6.00
Income statement
RevenueUS$81k
Gross profit-US$83k-102% margin
EBITDA-US$31M-38246% margin
Net income-US$31.9M-39417.3% margin
Valuation
PER (forward)-3.9x
P/Book1.4x
Beta1.06
Balance sheet & cash
Market capUS$81.7M
Total debtUS$2.3M
Free Cash Flow-US$26.3M
Debt / Equity5%
Profitability & ownership
ROE-45.0%
ROA-23.5%
% insiders12.1%
% institutions50.2%
Last declaration on 13 October 2026
Declarations264 total
8,024 shares@ US$2.03070.020% mcap47.6% of flowClass A CommonSEC144:0002091798-26-000009
8,024 shares@ US$2.030.020% mcap90.9% of flowClass A Common StockSEC:0002091798-26-000010:0
1,509 shares@ US$2.000.0035% mcap0.4% of flowClass A CommonSEC144:0001979974-26-000014
7,022 shares@ US$2.00010.017% mcap0.6% of flowClass A CommonSEC144:0001891299-26-000015
1,800 shares@ US$2.000.0042% mcap19.0% of flowClass A Common StockSEC:0002072324-26-000010:0
7,022 shares@ US$2.000.017% mcap0.6% of flowClass A Common StockSEC:0001891299-26-000016:0
486 shares@ US$2.000.0011% mcap57.1% of flowClass A Common StockSEC:0002091798-26-000008:0
2,190 shares@ US$2.000.0051% mcap0.9% of flowClass A Common StockSEC:0001779964-26-000010:0
20,139 shares@ US$2.00060.047% mcap1.9% of flowClass A CommonSEC144:0001891299-26-000011
13,591 shares@ US$2.0010.032% mcap3.8% of flowClass A CommonSEC144:0001979974-26-000012
20,139 shares@ US$2.000.047% mcap1.9% of flowClass A Common StockSEC:0001891299-26-000012:0
117,924 shares0Class A Common StockSEC:0001883387-26-000005:0
1,594 shares0Class A Common StockSEC:0001191080-26-000002:1
2,276 shares0Class A Common StockSEC:0001306386-26-000004:1
22,426 shares0Class A Common StockSEC:0001535065-26-000002:0
22,426 shares0Class A Common StockSEC:0001306386-26-000004:0
22,426 shares0Class A Common StockSEC:0001736026-26-000002:0
1,949 shares0Class A Common StockSEC:0001736026-26-000002:1
22,426 shares0Class A Common StockSEC:0001191080-26-000002:0
42,404 shares0Class A Common StockSEC:0001352413-26-000004:0
1,975 shares0Class A Common StockSEC:0001352413-26-000004:1
3,421 shares0Class A Common StockSEC:0001535065-26-000002:1
1,771 shares0Class A Common StockSEC:0001588389-26-000002:1
22,426 shares0Class A Common StockSEC:0001871555-26-000002:0
2,260 shares0Class A Common StockSEC:0001871555-26-000002:1
25 of 264 declarations
About Sera Prognostics, Inc.
Sera Prognostics, Inc. is a U.S.-based medical diagnostics company listed on the NASDAQ exchange in the United States. Incorporated in Delaware on January 17, 2008, the company is headquartered in Salt Lake City, Utah, where it also operates a CLIA-certified laboratory. Sera’s business model sits at the intersection of proteomics, bioinformatics, and clinical evidence, with a clear focus on women’s health and maternal-neonatal risk prediction. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001534969/000153496926000009/sera-20251231.htm?utm_source=openai))
The company’s flagship asset is the PreTRM blood test, designed to estimate the risk of spontaneous preterm birth in asymptomatic singleton pregnancies, typically drawn around weeks 18 to 20 of gestation. More broadly, Sera develops and commercializes blood-based biomarker tests and predictive analytics products and services intended to provide actionable information to physicians, pregnant women, and healthcare payers. Management has consistently framed the company’s ambition as becoming a global leader in high-value women’s health diagnostics, with a dual emphasis on better clinical outcomes and improved healthcare economics. ([sera.com](https://www.sera.com/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Sera operates in a specialized segment of reproductive and maternal health diagnostics where clinical validation, reimbursement access, and physician adoption are critical. Rather than competing as a broad diagnostics conglomerate, Sera’s differentiation is centered on a focused scientific platform and a product-led commercialization strategy. Over time, the company has invested in clinical studies, commercial infrastructure, and payer engagement to support adoption of PreTRM and related test-and-treat workflows. ([sera.com](https://www.sera.com/pregnancy-related-concerns/newsroom/sera-prognostics-completes-100-million-series-e-financing/?utm_source=openai))
Recent developments suggest that Sera is moving further from a clinical-stage profile toward a commercial organization. In 2026, the company said it had completed a comprehensive business review and was redirecting investment away from research-heavy activities toward reimbursement-driven commercialization, payer engagement, market access, and clinical adoption. Management also highlighted a longer cash runway and continued operational right-sizing. Separately, Sera has continued to publicize clinical evidence supporting PreTRM, including results from the PRIME and AVERT programs, which are intended to strengthen the case for early screening followed by targeted interventions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1534969/000153496926000025/sera-20260331.htm?utm_source=openai))
For investors, Sera should be viewed as a niche U.S. healthcare diagnostics company with an attractive clinical narrative, but one that still depends on successful reimbursement expansion, physician uptake, and sustained commercialization execution. Its positioning is distinct from a traditional biotech or large-cap diagnostics peer: the core value proposition is not therapeutic R&D, but a data-driven screening platform aimed at a large, under-addressed obstetric risk category. ([sera.com](https://www.sera.com/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
